Menu
Close
Our product portfolio is in constant development. We have committed to expanding the range of products we offer to patients in Latvia and other Western markets in order to keep improving the availability of medicines and help our patients on their way to better health.
Olpha will invest at least 22.25 million euros to product portfolio
expansion in 2024.
Behind every medicine available for improving
patients’ health is a detailed and extensive
development process consisting of various
stages.
The process is very time-consuming and
resource-intensive. It takes at least 2.5 to 6 years
from idea of the product until we can see it on a
pharmacy shelf.
